oppn parties Maiden Pharma Cough Syrup Case: Did WHO Act In Haste?

News Snippets

  • Allahabad HC said that the UP Police is acting as law unto themselves as they detained a person unlawfully even before his arrest
  • Kolkata witnesses traffic snarls on the first day of the Durga Puja festival as revellers start pnadal-hopping
  • Neha Bora was subsequently released and Dipke is to appear before a magistrate today at noon
  • Delhi Police detained Cockroach Janta Party founder Abhijeet Dipke, Neha Bora of AISA, student leaders and supporters ahead of a rally in Connaught Place demanding Chief Election Commissioner Gyanesh Kumar's resignation. The protest followed the detention and jailing of two CJP leaders earlier in the week over demonstrations at Jantar Mantar
  • The Reserve Bank of India is considering further monetary tightening to counter capital outflows and increase the cost of betting against the rupee, according to bankers and analysts cited by Reuters. The measures follow recent rate increases and steps to drain liquidity as pressure on the currency and inflation concerns persist
  • India directed oil marketing companies to stop diverting sugar-based feedstocks for ethanol production in the 2026–27 supply year, according to a new tender issued on Friday. The companies have invited bids for 11 billion litres of ethanol made from alternatives including corn and broken rice, amid concerns about domestic sugar supplies and prices
  • Finance Minister Nirmala Sitharaman said India's trade imbalance with China was growing sharply and attributed the problem partly to restrictions on Indian goods and services entering the Chinese market. China subsequently said it was ready to work with India to address mutual economic and trade concerns; India's trade deficit with China reached $69 billion in the first half of FY2026–27, up 27% year-on-year
  • Indian equity benchmarks extended their recovery on Friday, with the Sensex rising 413.66 points to close at 74,729.27 and the Nifty 50 gaining 148.80 points to settle at 23,146.15. Information technology shares, including Tech Mahindra, Infosys and TCS, helped lift the indices
  • India defeated Zimbabwe by four wickets in the opening women's T20 International in Raipur, taking a 1–0 lead in the three-match series. Deepti Sharma and Niki Prasad combined in an 82-run stand after India's top order collapsed, helping the hosts chase down Zimbabwe's total of 114 for five
  • Indian wrestler Komal won bronze in the women's 59 kg category at the Under-23 World Wrestling Championships in Las Vegas, defeating Kazakhstan's Viktoriia Khusainova 7–2. Fellow Indian Amruta Pujari advanced to the women's 72 kg final after recording two pinfall victories
  • Indian shuttler Jagsher Singh Khangurra secured a bronze medal at the BWF World Junior Badminton Championships in Cairo
  • The Supreme Court of India upheld the Bombay High Court's decision quashing the 2020 write-off of ₹8,415 crore in additional tier-1 bonds issued by Yes Bank (Yes Bank). The court ruled that the bank's administrator lacked the authority to extinguish the bonds under the final reconstruction scheme, strengthening bondholders' claims
  • The Supreme Court issued notices to the Election Commission of India, Delhi Police and opposition leaders, including Rahul Gandhi and Akhilesh Yadav, in separate petitions concerning electoral-roll revision and protests held in Delhi on October 10–12. The court also directed the preservation of CCTV footage linked to allegations of police excesses
  • The Supreme Court ruled that a person converting from Hinduism to Islam cannot automatically claim backward-class reservation benefits in the new religious community solely on the basis of their previous caste status. The judgment upheld the Madras High Court's decision striking down a 2024 Tamil Nadu government order that permitted such certification for specified communities
  • The Election Commission of India ordered a Special Summary Revision of electoral rolls in 14 states and three Union Territories, using January 1, 2027, as the qualifying date for voter eligibility. The draft rolls are scheduled for publication on November 12, claims and objections will be accepted until December 11, and the final rolls are due on January 4, 2027
Delhi HC refuses to ban CJP's Tiranga rally at Central Park in Connaught Place today /////// Police says will control and regulate it /////// NDMC closes the park for the public on Friday and Saturday
oppn parties
Maiden Pharma Cough Syrup Case: Did WHO Act In Haste?

By Sunil Garodia
First publised on 2022-12-16 06:50:54

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator. Author of Cyber Scams in India, Digital Arrest, The Money Trap and The Human Hack

A few months ago, the World Health Organization (WHO) had insinuated that India's Maiden Pharmaceuticals, the Haryana-based drug manufacturer, had supplied sub-standard paediatric cough syrups to Gambia and linked it to the death of 66 children in that country. Now, after the results of the tests conducted on the samples of final products and raw materials drawn from the manufacturing facilities of the drug firm have confirmed that there was nothing wrong with the syrups and they met with all prescribed standards, the government of India has slammed the WHO for drawing hasty conclusions and unfairly linking the death of the children to the alleged infirmities in the cough syrups without conducting a thorough test. Surprisingly, as the government has stated, WHO has, till now, refused to share any details as to how it arrived at the conclusion that linked the deaths to the cough syrups despite several reminders.

The hasty action of WHO is not acceptable, more so as it has failed to produce material to support the claims. India has earned the reputation of supplying excellent quality pharmaceuticals products all over the world. Its companies follow good manufacturing practices and are being regularly inspected by local authorities and even international authorities. If baseless charges, not backed by supporting material, are made against one Indian company it will damage the reputation of the entire industry.

India must take up the matter with WHO at the highest level. It should submit the findings of the tests conducted and demand the same from WHO. If WHO is unable to substantiate its claims then it should issue an unconditional apology and clear the drug manufacturer. Further, there must a defined process at WHO through which such alerts are issued. It must do so only after conducting acceptable preliminary tests and provide the results to the government of the originating country. In case of Maiden Pharmaceuticals it seems that WHO is trying to hide its inefficiency as it has failed to provide supporting material even though nearly three months have passed since it first sounded the alert. This is damaging for the whole pharmaceuticals ecosystem.